Malaysia’s stem cell therapy industry is getting a major boost. Yakin Medic Sdn Bhd, a key player in regenerative medicine, has announced plans to go public on the Singapore Exchange (SGX) Catalist Board in late 2025 or early 2026.
The company aims to raise RM100 million, with RM70 million dedicated to developing a new stem cell manufacturing facility in Cyberjaya. (Business Today)
What This Means for Patients & Healthcare
Yakin Medic’s expansion isn’t just about business—it could transform healthcare access and medical tourism in Malaysia.
More Access to Stem Cell Therapy – The Cyberjaya facility is set to produce stem cells for 5,000 patients annually by 2027, targeting conditions like diabetes. (The Sun Daily)
Boosting Malaysia’s Medical Tourism – The country is already a global hotspot for medical tourism, and Yakin Medic’s growth could attract more international patients seeking cutting-edge treatments.
Investment in Innovation – With the IPO funds, Yakin Medic will expand overseas, invest in R&D, and set up satellite laboratories to further develop its stem cell technology. (The Edge Malaysia)
A Step Closer to Affordable Regenerative Medicine?
Stem cell therapy is revolutionizing healthcare, offering hope for treating chronic diseases and tissue regeneration. But cost and accessibility remain challenges.
With this IPO, Yakin Medic is positioning itself as a leader in affordable, high-quality regenerative treatments in Asia. If successful, this could mark a turning point in making stem cell therapy mainstream in Malaysia.
What’s Next?
The IPO process is ongoing, with MCI Capital Sdn Bhd investing through the ASIA IPO FUND, which supports SMEs like Yakin Medic in scaling up. (Business Today)
What do you think—will stem cell therapy become a game changer for Malaysia’s healthcare scene?
More info: Yakin Medic Official Website
